Evaluating treatment effect based on duration of response for a comparative oncology study

Roy Mano, Shlomit Tamir, Inbal Kedar, Ofer Benjaminov, Jack Baniel, Tzlil Tabachnik, David Margel

Research output: Contribution to journalLetterpeer-review

18 Scopus citations
Original languageEnglish
Pages (from-to)874-876
Number of pages3
JournalJAMA Oncology
Issue number6
StatePublished - Jun 2018
Externally publishedYes

Bibliographical note

Funding Information:
Funding/Support: This work was partially supported by the American Society of Clinical Oncology career development award (grant No. 8259); the Israeli Cancer Association; and the German Israeli Foundation (grant No. 2393). Role of the Funder/Sponsor: The American Society of Clinical Oncology, the Israeli Cancer Association, and the German Israeli Foundation had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. Additional Contributions: We thank Yaara Ber, PhD, Sivan Sela, BSc, and Rachel Ozalvo, MA, all at the Urology research unit at Rabin Medical Center, for their assistance in data collection and analysis. They were not compensated. 1. Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE; Breast Cancer Linkage Consortium. Risks of cancer in BRCA1-mutation carriers. Lancet. 1994;343 (8899):692-695. 2. Breast Cancer Linkage C; Breast Cancer Linkage Consortium. Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst. 1999;91(15):1310-1316. 3. Liede A, Karlan BY, Narod SA. Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature. J Clin Oncol. 2004;22 (4):735-742. 4. Castro E, Goh C, Olmos D, et al. Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. J Clin Oncol. 2013;31(14):1748-1757. 5. National Comprehensive Cancer Network. Genetic/Familial High-Risk Assessment: Breast and Ovarian (Version 1.2017). https://www.nccn.org /professionals/physician_gls/pdf/genetics_screening.pdf. 6. Bancroft EK, Page EC, Castro E, et al; IMPACT Collaborators. Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study. Eur Urol. 2014;66(3): 489-499.

Funding Information:
Funding/Support: This research was partially supported by US National Institutes of Health grants and contracts. The procedure presented here is implemented via computer code available in (https://web.stanford.edu/~lutian /Software.HTML).

Cite this